CPA
ABOS icon

Capital Performance Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Capital Performance Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-52
Closed -$129 – 181
2024
Q3 		$129 Buy
+52
New +$141 ﹤0.01% 2651

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Capital Performance Advisors's ABOS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q4 2024, closing a stake of 52 shares — an estimated $129 sold.

Capital Performance Advisors first reported a position in ABOS in Q3 2024 and held it in 1 quarter. The position peaked at $129 in Q3 2024. 80 funds tracked by Wall St. Rank hold ABOS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Acumen Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 52 Acumen Pharmaceuticals shares in Q4 2024, an estimated $129.
  • Capital Performance Advisors first reported a position in Acumen Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Acumen Pharmaceuticals position peaked at $129 in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.